Comparison of tear proteomic and neuromediator profiles changes between small incision lenticule extraction (SMILE) and femtosecond laser-assisted in-situ keratomileusis (LASIK)

Liu, Yu‐Chi; Yam, Gary Hin‐Fai; Lin, Molly Tzu-Yu; Teo, Ericia Pei Wen; Koh, Siew-Kwan; Lu, Dunyue; Zhou, Lanlan; Tong, Louis

doi:10.1016/j.jare.2020.11.001

Cited by 32 publications

(20 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, B lymphocytes secrete Igs, also known as antibodies that mediate the effector phase of humoral immunity [54]. Recently, some research showed significant changes in Igs in tear protein profiles in specific diseases like diabetic retinopathy, primary open-angle glaucoma, and postrefractive surgery [55,56]. In our study, we found a decrease in Ig heavy variable 5-10-1 in the iERM group.…”

Section: Discussionsupporting

confidence: 61%

Aqueous Lumican Correlates with Central Retinal Thickness in Patients with Idiopathic Epiretinal Membrane: A Proteome Study

et al. 2022

View full text Add to dashboard Cite

Idiopathic epiretinal membrane (iERM) is a pathological fibrocellular change in the vitreoretinal junction over the macular area; however, possible pathogenic mechanisms remain unclear. Changes in the differential protein composition of the aqueous humor (AH) may represent potential molecular changes associated with iERM. To gain new insights into the molecular mechanisms of iERM pathology, a sensitive label-free proteomics analysis was performed to compare AH protein expressions in patients with cataracts with or without iERM. This study employed nanoflow ultra-high-performance liquid chromatography-tandem mass spectrometry to investigate protein compositions of the AH obtained from individual human cataract eyes from 10 patients with iERM and 10 age-matched controls without iERM. Eight proteins were differentially expressed between the iERM and control samples, among which six proteins were upregulated and two were downregulated. A gene ontology (GO) analysis revealed that iERM was closely associated with several biological processes, such as immunity interactions, cell proliferation, and extracellular matrix remodeling. Additionally, multiple proteins, including lumican, cyclin-dependent kinase 13, and collagen alpha-3(VI) chain, were correlated with the central retinal thickness, indicating a multifactorial response in the pathogenic process of iERM. Changes in the AH level of lumican between iERM and control samples were also confirmed by an enzyme-linked immunosorbent assay. In conclusion, several pathological pathways involved in iERM were identified in the AH by a proteomic analysis, including immune reactions, cell proliferation, and remodeling of the extracellular matrix. Lumican is a potential aqueous biomarker for predicting iERM development and monitoring its progression. More clinical parameters also need to be identified to complete the analysis, and those could provide additional targets for treating and preventing iERM.

show abstract

Section: Discussionsupporting

confidence: 61%

Aqueous Lumican Correlates with Central Retinal Thickness in Patients with Idiopathic Epiretinal Membrane: A Proteome Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Quantitative tear proteomic analysis was performed as previously described (25). The Schirmer strips were cut into small pieces, and 100 μl lysis buffer was added and mixed in a Thermomixer for 1.5 hours at 20 ºC.…”

Section: Tear Proteomic Analysismentioning

confidence: 99%

Oral Peroxisome Proliferator-Activated Receptor-Alpha (PPAR)-α Agonist Enhances Corneal Nerve Regeneration in Patients with Type II Diabetes Mellitus

Teo¹,

Lin²,

Lee³

et al. 2022

Preprint

View full text Add to dashboard Cite

<p>Diabetic corneal neuropathy (DCN) is a common complication of diabetes mellitus (DM). However, there are very limited therapeutic options. We investigated the effects of a peroxisome proliferator-activated receptor-alpha (PPAR)-α agonist, fenofibrate, on thirty patients (60 eyes) with type II DM. On in-vivo confocal microscopy evaluation, there was significant stimulation of corneal nerve regeneration and a reduction in nerve edema after 30 days of oral fenofibrate treatment, evidenced by the significant improvement in corneal nerve fiber density (CNFD) and corneal nerve fiber width, respectively. Corneal epithelial cells morphology also significantly improved in its cell circularity. Upon clinical examination, fenofibrate significantly improved patients’ neuropathic ocular surface status by increasing tear break-up time along with a reduction of corneal and conjunctival punctate keratopathy. Tear substance P (SP) concentrations significantly increased after treatment, suggesting an amelioration of ocular surface neuroinflammation. The changes in tear SP concentrations was also significantly associated with the improvement in CNFD. Quantitative proteomic analysis demonstrated that fenofibrate significantly upregulated and modulated the neurotrophin signalling pathway, linolenic acid, cholesterol and fat metabolism. Complement cascades, neutrophil reactions, and platelet activation were also significantly suppressed. Our results showed that fenofibrate could potentially be a novel treatment for patients with DCN.</p>

show abstract

“…[ 37 38 ] Both RCLE and LASIK induce a transient worsening in dry eye parameters, but there is evidence showing that RCLE has a less negative impact on ocular surface parameters and allows for an earlier recovery. [ 37 39 ] Analyzing ocular surface changes in 15 patients post SMILE and 32 post FS-LASIK, Gao et al . found lower fluorescein staining scores after 1 week, longer tear breakup times after 1 and 3 months, higher central corneal sensitivity at 1 week, 1 and 3 months as well as lower levels and a faster decrease of interleukin-6 and nerve growth factor in tears following SMILE compared to FS-LASIK.…”

Section: Advantages Of Refractive Corneal Lenticule Extractionmentioning

confidence: 99%

Advances in refractive corneal lenticule extraction

Fuest

2021

Taiwan Journal of Ophthalmology

View full text Add to dashboard Cite

Refractive errors are the leading cause of reversible visual impairment worldwide. In addition to the desired spectacle independence, refractive procedures can improve quality of life, working ability, and daily working performance. Refractive corneal lenticule extraction (RCLE) is a relatively new technique, dependent only on a femtosecond laser (FS). This leads to potential benefits over laser-assisted in situ keratomileusis (LASIK) including a quicker recovery of dry eye disease, a larger functional optical zone, and no flap-related complications. SMILE, available with the VisuMax FS (Carl Zeiss Meditec AG, Jena, Germany), is the most established RCLE application, offering visual and refractive outcomes comparable to LASIK. SmartSight (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany) and CLEAR (Ziemer Ophthalmic Systems AG, Port, Switzerland) are two new RCLE applications that received Conformité Européenne (CE) approval in 2020. In this article, we review refractive and visual outcomes, advantages, and disadvantages of RCLE and also report on the latest advances in RCLE systems.

show abstract

Comparison of tear proteomic and neuromediator profiles changes between small incision lenticule extraction (SMILE) and femtosecond laser-assisted in-situ keratomileusis (LASIK)

Abstract: Graphical abstract

Cited by 32 publications

References 53 publications

Aqueous Lumican Correlates with Central Retinal Thickness in Patients with Idiopathic Epiretinal Membrane: A Proteome Study

Aqueous Lumican Correlates with Central Retinal Thickness in Patients with Idiopathic Epiretinal Membrane: A Proteome Study

Oral Peroxisome Proliferator-Activated Receptor-Alpha (PPAR)-α Agonist Enhances Corneal Nerve Regeneration in Patients with Type II Diabetes Mellitus

Advances in refractive corneal lenticule extraction

Contact Info

Product

Resources

About